Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations

被引：13
|
作者：
Davis, Alexander P. [1 ]
Cooper, Wendy A. [2 ,3 ,4 ]
Boyer, Michael [1 ,5 ]
Lee, Jenny H. [1 ,6 ]
Pavlakis, Nick [5 ,7 ,8 ]
Kao, Steven C. [1 ,5 ,9 ]
机构：
[1] Chris OBrien Lifehouse, Dept Med Oncol, 119-143 Missenden Rd, Camperdown, NSW 2050, Australia
[2] Royal Prince Alfred Hosp, Tissue Pathol & Diagnost Oncol, Sydney, NSW 2050, Australia
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW 2050, Australia
[4] Western Sydney Univ, Sch Med, Sydney, NSW 2571, Australia
[5] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia
[6] Macquarie Univ, Fac Med & Hlth, N Ryde, NSW 2109, Australia
[7] Royal North Shore Hosp, Dept Med Oncol, St Leonards, NSW 2065, Australia
[8] Genesis Care St Leonards, St Leonards, NSW 2065, Australia
[9] Asbestos Dis Res Inst, Concord, NSW 2139, Australia
来源：
IMMUNOTHERAPY | 2021年 / 13卷 / 11期
关键词：
comutations; immune checkpoint inhibitors; KEAP1; KRAS; LKB1; NSCLC; STK11; TP53; COOCCURRING GENOMIC ALTERATIONS; PLATINUM-BASED CHEMOTHERAPY; CHECKPOINT INHIBITORS; KRAS(G12C) INHIBITOR; PEMBROLIZUMAB PEMBRO; TUMOR-SUPPRESSOR; GENE-ALTERATION; ATM MUTATIONS; OPEN-LABEL; AMG; 510;
D O I：
10.2217/imt-2021-0090
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
KRAS-mutant non-small-cell lung cancer is the most common molecular driver of lung adenocarcinoma in western populations. No KRAS specific therapy has been approved by the FDA until 2021. Despite significant heterogeneity in comutations, patients typically receive single-agent immunotherapy or chemoimmunotherapy as standard first-line therapy. It is unclear whether KRAS mutations predict outcomes with immunotherapy; however, there is emerging data suggesting improved outcomes in patients with a TP53 comutation and worse outcomes in patients with a STK11/LKB1 or KEAP1 comutation.
引用
收藏
页码：941 / 952
页数：12
相关论文
共 50 条
  • [1] Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ
    Lee, Wen-Ying
    Chen, Pin-Cyuan
    Wu, Wen-Shin
    Wu, Han-Chung
    Lan, Chun-Hsin
    Huang, Yen-Hua
    Cheng, Chia-Hsiung
    Chen, Ku-Chung
    Lin, Cheng-Wei
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (09) : 1921 - 1931
  • [2] The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer
    Goldberg, Sarah B.
    Herbst, Roy S.
    [J]. LANCET, 2023, 401 (10378): : 706 - 707
  • [3] KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
    Ceddia, Serena
    Landi, Lorenza
    Cappuzzo, Federico
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (16)
  • [4] Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer
    Metro, Giulio
    Chiari, Rita
    Baldi, Alice
    De Angelis, Verena
    Minotti, Vincenzo
    Crino, Lucio
    [J]. FUTURE ONCOLOGY, 2013, 9 (02) : 167 - 177
  • [5] Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer
    Shimamura, Takeshi
    Chen, Zhao
    Soucheray, Margaret
    Carretero, Julian
    Kikuchi, Eiki
    Tchaicha, Jeremy H.
    Gao, Yandi
    Cheng, Katherine A.
    Cohoon, Travis J.
    Qi, Jun
    Akbay, Esra
    Kimmelman, Alec C.
    Kung, Andrew L.
    Bradner, James E.
    Wong, Kwok-Kin
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6183 - 6192
  • [6] SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
    Mainardi, Sara
    Mulero-Sanchez, Antonio
    Prahallad, Anirudh
    Germano, Giovanni
    Bosma, Astrid
    Krimpenfort, Paul
    Lieftink, Cor
    Steinberg, Jeffrey D.
    de Wit, Niels
    Goncalves-Ribeiro, Samuel
    Nadal, Ernest
    Bardelli, Alberto
    Villanueva, Alberto
    Bernards, Rene
    [J]. NATURE MEDICINE, 2018, 24 (07) : 961 - +
  • [7] SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
    Sara Mainardi
    Antonio Mulero-Sánchez
    Anirudh Prahallad
    Giovanni Germano
    Astrid Bosma
    Paul Krimpenfort
    Cor Lieftink
    Jeffrey D. Steinberg
    Niels de Wit
    Samuel Gonçalves-Ribeiro
    Ernest Nadal
    Alberto Bardelli
    Alberto Villanueva
    Rene Bernards
    [J]. Nature Medicine, 2018, 24 : 961 - 967
  • [8] Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
    Jeanson, Arnaud
    Tomasini, Pascale
    Souquet-Bressand, Maxime
    Brandone, Nicolas
    Boucekine, Mohamed
    Grangeon, Mathieu
    Chaleat, Solene
    Khobta, Natalyia
    Milia, Julie
    Mhanna, Laurent
    Greillier, Laurent
    Biemar, Julie
    Nanni, Isabelle
    Ouafik, L'houcine
    Garcia, Stephane
    Mazieres, Julien
    Barlesi, Fabrice
    Mascaux, Celine
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) : 1095 - 1101
  • [9] A differential analysis of TCR repertoire between patients with EGFR-mutant and KRAS-mutant non-small-cell lung cancer
    Xie, Yuancai
    Li, Yingmei
    Dong, Linfeng
    Chen, Shifu
    Liu, Jixian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Evaluating Racial Differences in KRAS-Mutant Non-Small Cell Lung Cancer
    Aredo, J.
    Padda, S.
    Kunder, C.
    Han, S.
    Wakelee, H.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1133 - S1133
12345